The anti-C5 monoclonal antibody eculizumab has been used in COVID-19 patients [27], but a study evaluating the longer-acting anti-C5 monoclonal antibody ravulizumab was discontinued early due to lack of efficacy. This evidence concerns the gene C5 and COVID-19.